Bueb J L, Landry Y
Laboratoire de Neuroimmunopharmacologie, Université Louis-Pasteur, Illkirch.
Ann Dermatol Venereol. 1990;117 Suppl 1:5-9.
Human cutaneous mast cells and their experimental model rat peritoneal mast cells, can be stimulated by an IgE-dependent process or by peptides through the direct activation of G proteins. Both activation pathways lead to the increase of cytosolic Ca2+ level. This increase in dependent of the mobilisation of intracellular calcium stores of the endoplasmic reticulum involving the stimulation of IP3-sensitive calcium channels. Mast cells are characterized by the absence of calcium channels in the plasma membrane. Oxatomide has been synthetized as an analog of cinnarizine. However oxatomide is inactive on current calcium channels. In mast cells, oxatomide inhibits the increase of cytosolic calcium elicited during mast cell activation. Consequently mast cell exocytosis is inhibited altogether with the release of newly synthetized mediators. The authors propose several putative targets for oxatomide in mast cells. The therapeutic effect of oxatomide is also related to its property to antagonize the effects of anaphylactic mediators on their selective receptors.
人类皮肤肥大细胞及其实验模型大鼠腹膜肥大细胞,可通过IgE依赖过程或通过肽直接激活G蛋白来刺激。这两种激活途径都会导致胞质Ca2+水平升高。这种升高依赖于内质网细胞内钙库的动员,涉及对IP3敏感钙通道的刺激。肥大细胞的特征是质膜中不存在钙通道。奥沙米特已被合成作为桂利嗪的类似物。然而,奥沙米特对当前的钙通道无活性。在肥大细胞中,奥沙米特抑制肥大细胞激活期间引起的胞质钙增加。因此,肥大细胞胞吐作用与新合成介质的释放一起被完全抑制。作者提出了奥沙米特在肥大细胞中的几个假定靶点。奥沙米特的治疗作用还与其拮抗过敏介质对其选择性受体的作用的特性有关。